Phase 1/2 × Terminated × Burkitt Lymphoma × Clear all
NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
58 enrolled 11 charts
NCT00788125 2023-07-14

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

City of Hope Medical Center

Phase 1/2 Terminated
7 enrolled 9 charts
NCT01805037 2021-09-01

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Northwestern University

Phase 1/2 Terminated
20 enrolled 17 charts
NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
69 enrolled 34 charts
NCT00295880 2017-12-28

Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
12 enrolled 14 charts
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
NCT00089076 2014-05-30

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
18 enrolled 11 charts
NCT00006220 2013-02-06

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Washington University School of Medicine

Phase 1/2 Terminated
5 enrolled